Clinical trials: Carcinoma, Merkel Cell
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Carcinoma, Merkel Cell
Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
The purpose of this trial is to evaluate the efficacy of lanreotide on locally evolving and/or metastatic MCC in a national prospective multicentre phase II study (centres belonging to the skin cancer task force of the French…
- Trial name
- PHRC-Merkel (NCT02351128)
- Testing
- Lanreotide
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Grenoble
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
This phase II trial tests how well a combination of three immunotherapy drugs work for patients with Merkel cell carcinoma that has spread to lymph nodes and/or distant parts of the body and cannot be treated with surgery…
- Conditions
- Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
- Trial name
- TRICK-MCC (NCT06056895)
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Merkel Cell Carcinoma
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
There is no standard treatment for Merkel cell carcinoma(MCC), as no randomized trials have been conducted to establish standard of care.
- Trial name
- NCT02054884
- Testing
- Arm A: F16IL2 in combination with paclitaxel, Arm B: Paclitaxel
- Where
- 8 sites in Austria, Denmark and 4 more
- Volunteers
- 13 people
- Sponsor
- Philogen S.p.A.
Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
This phase II trial is studying how well imatinib mesylate works in treating patients with metastatic or unresectable Merkel cell cancer.
- Conditions
- Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin, Stage III Neuroendocrine Carcinoma of the Skin
- Trial name
- NCT00068783
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma, Merkel Cell Carcinoma
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
This study is to compare the ability of optical biopsy. Research can use light enters the skin, collected, analyzed by the computer, and a picture created for the pathologist to conventional histologic examination compare with…
- Conditions
- Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT00540566
- Testing
- Optical Biopsy imaging
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Merkel Cell Carcinoma
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
- Trial name
- NCT04874831
- Testing
- domatinostat in combination with avelumab
- Sponsor
- 4SC AG
Primary Visceral Tumors of Any Histotype, Visceral Lesions
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy.
- Conditions
- Primary Visceral Tumors of Any Histotype, Visceral Lesions, Liver Cancer, Liver Metastasis Colon Cancer
- Trial name
- NCT06753136
- Testing
- percutaneous, laparoscopic or laparotomy lesion electrochemotherapy
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Merkel Cell Carcinoma
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation
Primary objective: To estimate the efficacy of adjuvant nivolumab monotherapy in completely resected MCC patients Primary endpoint: Disease-free survival (DFS) rate evaluated at 12, 24 and 48 months after date of randomization…
- Trial name
- ADMEC-O (NCT02196961)
- Testing
- Nivolumab
- Where
- 20 sites in Germany, Netherlands
- Volunteers
- 180 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Merkel Cell Carcinoma
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence.
- Trial name
- MCC (NCT05496036)
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Neuroendocrine Tumors, Insulinoma
DOTATOC PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Conditions
- Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma
- Trial name
- NCT03583528
- Testing
- 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- British Columbia Cancer Agency
Malignant Neoplasm, Carcinoma, Merkel Cell
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer.
- Conditions
- Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma
- Trial name
- NCT07302347
- Testing
- Pembrolizumab
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Merkel Cell Carcinoma, Islet Cell Carcinoma
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
- Trial name
- NCT00003514
- Testing
- antineoplaston A10, antineoplaston AS2-1, alternative product therapy
- Where
- United States
- Sponsor
- Burzynski Research Institute
Cutaneous Melanoma, Mucosal Melanoma
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
- Trial name
- NCT07600476
- Testing
- KUP-101A
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kupando GmbH
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Carcinoma of Unknown Primary, Neuroendocrine Carcinoma
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have advanced…
- Conditions
- Carcinoma of Unknown Primary, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma of the Skin
- Trial name
- NCT00004922
- Testing
- irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Merkel Cell Carcinoma
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.
- Trial name
- NCT03089658
- Testing
- Avelumab
- Where
- France
- Sponsor
- Merck KGaA, Darmstadt, Germany
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca